Withdrawal Effects of Lunesta (Eszopiclone)
Lunesta withdrawal is generally mild and occurs in approximately 10% of patients after long-term use, primarily manifesting as anxiety, abnormal dreams, nausea, and upset stomach within 48 hours of discontinuation 1.
Specific Withdrawal Symptoms
The FDA label for Lunesta explicitly identifies the following withdrawal symptoms that meet DSM-IV criteria for uncomplicated sedative/hypnotic withdrawal 1:
- Anxiety
- Abnormal dreams
- Nausea
- Upset stomach
Additional symptoms reported in clinical studies include 2:
- Hyperesthesia (increased sensitivity to stimuli)
- Diarrhea
These symptoms typically occur within 48 hours after the last dose and have an incidence of 2% or less in clinical trials 1.
Clinical Significance and Risk Factors
The withdrawal profile of Lunesta is notably milder than traditional benzodiazepines. A prospective study found that only 10.5% of patients developed clinically relevant withdrawal symptoms (defined as BHWSS score ≥7) after 24 weeks of treatment with eszopiclone 2 mg followed by abrupt discontinuation 3.
The key predictor of withdrawal symptoms is dependence and poor medication compliance during treatment, not the severity of insomnia itself 3. Patients who showed problematic use patterns, preoccupation with the medication, or lack of compliance were significantly more likely to experience withdrawal (odds ratio 1.650, p=0.014) 3.
Important Clinical Distinctions
No Serious Withdrawal Syndrome
Unlike benzodiazepines, clinical trials revealed no evidence of a serious withdrawal syndrome with Lunesta 1. Multiple studies confirm:
- No rebound insomnia after discontinuation 4, 5
- No serious withdrawal effects 4, 5
- No tolerance development during up to 12 months of treatment 4, 5, 2
Exception: Higher Doses and Specific Populations
One study noted rebound insomnia occurred with 2 mg doses in non-elderly subjects, but this was not observed with 3 mg doses 2. However, a more recent mechanistic study found that patients using eszopiclone had more difficulty discontinuing compared to zolpidem or placebo, particularly those with hyperarousal 6.
Discontinuation Protocol
Gradual tapering is recommended despite the mild withdrawal profile 7, 8. Current European consensus guidelines recommend:
- Dose reductions of 10-25% per week 8
- Consider cross-tapering with:
- Multi-component CBT-I
- Daridorexant (DORA)
- Melatonin 2 mg prolonged-release 8
The FDA label warns that abrupt discontinuation can produce withdrawal symptoms similar to other CNS depressants, though the actual incidence remains low 1.
Critical Caveats
Dependence risk increases with: dose, duration of treatment, concomitant use of other psychoactive drugs, and history of alcohol/drug abuse or psychiatric disorders 1
Providing guidance for proper medication compliance is the best strategy to mitigate withdrawal symptoms 3
Most patients (51%) successfully discontinued without any medication during a 2-week taper period, and among those who continued, usage declined from week one to week two 6
Post-discontinuation insomnia severity was not significantly different between patients with and without withdrawal symptoms 3, suggesting withdrawal is distinct from return of underlying insomnia
The evidence consistently demonstrates that Lunesta has a favorable withdrawal profile compared to benzodiazepines, with mild, self-limited symptoms affecting a minority of patients 7, 1, 4, 5.